Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients

Overview of attention for article published in Journal of Oncology Pharmacy Practice, April 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 15 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 2,049 followers.

Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. https://t.co/iqbv2TXGPt

28 Apr 2020

Reply Repost Favourite

Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. https://t.co/1rXNfn5mfB

28 Apr 2020

Reply Repost Favourite

New article: Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. https://t.co/PVvUmhF5Qa #AML #leusm #hematology

28 Apr 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.